Therapeutic recombinant proteins: Trends in US approvals 1982 to 2002

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 2, 2003, Pages 139-147

  Reichert, Janice M ^a   Paquette, Cherie ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Approval success rate; Biotechnology; Clinical study; Food and Drug Administration approval; Therapeutic recombinant protein

Indexed keywords

ALTEPLASE; BECAPLERMIN; BETA1A INTERFERON; BIO TROPIN; CONSENSUS INTERFERON; DORNASE ALFA; ETANERCEPT; GLUCAGON; HUMAN GROWTH HORMONE; HUMAN INSULIN; IMIGLUCERASE; INSULIN; INSULIN LISPRO; INTERFERON BETA SERINE; LEPIRUDIN; NOVOLIN R; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GLUCAGON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; RETEPLASE; SOMATREM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALYTIC METHOD; CALCULATION; CLINICAL STUDY; DATA ANALYSIS; DRUG APPROVAL; DRUG INDICATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; REVIEW; TIME; UNITED STATES;

DRUG APPROVAL; DRUG THERAPY; RECOMBINANT PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0038576283     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Reichert JM: Therapeutic monoclonal antibodies: Trends in development and approval in the US. Curr Opin Mol Ther (2002) 4(2):110-118.
2. Reichert JM, Paquette C: Therapeutic cancer vaccines on trial. Nat Biotechnol (2002) 20(7):659-663.
3. Watson JD, Crick FHC: Molecular structure of nucleic acids: A structure for deoxyribonucleic acid. Nature (1953) 171:737-738.
4. Watson JD, Crick FHC: Genetic implications of the structure of deoxyribonucleic acid. Nature (1953) 171:964-967.
5. Stent GS: That was the molecular biology that was. Science (1968) 160:390-395.
6. Smith HO, Wilcox KW: A restriction enzyme from Haemophilus influenzae I. Purification and general properties. J Mol Biol (1970) 51(2):379-391.
7. Kelly TJ Jr, Smith HO: A restriction enzyme from Haemophilus influenzae II. Base sequence of the recognition site. J Mol Biol (1970) 51(2):393-409.
8. Jackson DA, Symons RH, Berg P: Biochemical method for inserting new genetic information into DNA of simian virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA (1972) 69(10):2904-2909.
9. Cohen SN, Chang ACY, Boyer HW, Helling RB: Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci USA (1973) 70(11):3240-3244.
10. Morrow JF, Cohen SN, Chang ACY, Boyer HW, Goodman HM, Helling RB: Replication and transcription of eukaryotic DNA In Escherichia coli. Proc Natl Acad Sci USA (1974) 71(5):1743-1747.
11. Maxam AM, Gilbert W: A new method for sequencing DNA. Proc Natl Acad Sci USA (1977) 74(2):560-564.
12. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA (1977) 74(12):5463-5467.
13. Reichert JM, Chee J, Kotzampaltiris CS: The effects of the Prescription Drug User Fee Act (PDUFA) and the Food and Drug Administration Modernization Act (FDAMA) on the development and approval of therapeutic medicines. Drug Inf J (2001) 35(1):85-94.
14. Gosse ME, Manocchia M: The first biopharmaceuticals approved in the United States: 1980-1994. Drug Inf J (1996) 30(4):991-1001.
15. Reichert JM: New biopharmaceuticals in the USA: Trends in development and marketing approvals 1995-1999. Trends Biotechnol (2000) 18(9):364-369.
16. Kaitin KI, Manocchia M: The new drug approvals of 1993, 1994 and 1995: Trends in drug development. Am J Ther (1997) 4(1):46-54.
17. Kaitin KI, Healy E: The new drug approvals of 1996, 1997 and 1998: Drug development trends in the user fee era. Drug Inf J (2000) 34(1):1-14.
18. Kaitin KI: Approval times for new drugs fell by more than a year during PDUFA but clinical development time for some therapeutic areas remains lengthy. Tufts Center for the Study of Drug Development Impact Report (2002) 4:1-4.
19. DiMasi JA: Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther (2001) 69(5):297-307.